Goldman Sachs’s AIM ImmunoTech AIM Stock Holding History

Goldman Sachs’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.21K	Buy	+32,444	New	+$14.8K	﹤0.01%	6482
2020 Q2	–	Sell	-148	Closed	-$38K	–	5697
2020 Q1	$38K	Buy	+148	New	+$23.2K	﹤0.01%	5078
2016 Q3	–	Hold	0	–	-$3K	–	7499
2016 Q2	–	Hold	0	–	–	–	6969
2016 Q1	–	Hold	0	–	–	–	7021
2015 Q4	–	Sell	-1	Closed	-$6.8K	–	7111
2015 Q3	$5K	Hold	1	–	–	﹤0.01%	7212
2015 Q2	$6K	Buy	+1	New	+$12.4K	﹤0.01%	7197
2015 Q1	–	Hold	0	–	–	–	7006
2014 Q4	–	Hold	0	–	–	–	7068
2014 Q1	–	Hold	0	–	-$6K	–	7174
2013 Q4	–	Hold	0	–	–	–	6602
2013 Q3	–	Hold	0	–	–	–	6512
2013 Q2	–	Hold	0	–	–	–	6290

Other funds holding AIM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Continuum Advisory Eagle, Idaho $1.24B AUM 30.12% 1-Year Est. Return

Goldman Sachs's AIM Position: Q2 2026 in Review

Goldman Sachs opened a new position in AIM ImmunoTech (AIM) in Q2 2026: 32,444 shares worth $9.21K. The stake represents ﹤0.01% of the portfolio and ranks #6482 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in AIM as recently as Q1 2020.

Goldman Sachs first reported a position in AIM in Q2 2015 and has held it in 4 quarters since. The position peaked at $38K in Q1 2020. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

Goldman Sachs held 32,444 shares of AIM ImmunoTech worth $9.21K as of Q2 2026.
AIM ImmunoTech was a new Goldman Sachs position in Q2 2026.
AIM ImmunoTech made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6482 holding.
Goldman Sachs first reported a position in AIM ImmunoTech in Q2 2015 and has held it in 4 quarters since.
Goldman Sachs's AIM ImmunoTech position peaked at $38K in Q1 2020.
18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.